The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial
Open accessAbstract
Importance: Complete metastatic ablation of oligometastatic prostate cancer may provide an alternative to early initiation of androgen deprivation therapy (ADT). Objective: To determine if stereotactic ablative radiotherapy (SABR) improves oncologic outcomes in men with oligometastatic prostate cancer. Design, Setting, and Participants: The Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer (ORIOLE) phase 2 randomized study accrued participants from 3 US radiation treatment facilities affiliated with a university hospital from May 2016 to March 2018 with a data cutoff date of May 20, 2019, for analysis. Of 80 men screened, 54 men with recurrent hormone-sensitive prostate cancer and 1 to 3 metastases detectable by conventional imaging who had not received ADT within 6 months of enrollment or 3 or more years total were randomized. Interventions: Patients were randomized in a 2:1 ratio to receive SABR or observation. Main Outcomes and Measures: The primary outcome was progression at 6 months by prostate-specific antigen level increase, progression detected by conventional imaging, symptomatic progression, ADT initiation for any reason, or death. Predefined secondary outcomes were toxic effects of SABR, local control at 6 months with SABR, progression-free survival, Brief Pain Inventory (Short Form)-measured quality of life, and concordance between conventional imaging and prostate-specific membrane antigen (PSMA)-targeted positron emission tomography in the identification of metastatic disease. Results: In the 54 men randomized, the median (range) age was 68 (61-70) years for patients allocated to SABR and 68 (64-76) years for those allocated to observation. Progression at 6 months occurred in 7 of 36 patients (19%) receiving SABR and 11 of 18 patients (61%) undergoing observation (P = .005). Treatment with SABR improved median progression-free survival (not reached vs 5.8 months; hazard ratio, 0.30; 95% CI, 0.11-0.81; P = .002). Total consolidation of PSMA radiotracer-avid disease decreased the risk of new lesions at 6 months (16% vs 63%; P = .006). No toxic effects of grade 3 or greater were observed. T-cell receptor sequencing identified significant increased clonotypic expansion following SABR and correlation between baseline clonality and progression with SABR only (0.082085 vs 0.026051; P = .03). Conclusions and Relevance: Treatment with SABR for oligometastatic prostate cancer improved outcomes and was enhanced by total consolidation of disease identified by PSMA-targeted positron emission tomography. SABR induced a systemic immune response, and baseline immune phenotype and tumor mutation status may predict the benefit from SABR. These results underline the importance of prospective randomized investigation of the oligometastatic state with integrated imaging and biological correlates. Trial Registration: ClinicalTrials.gov Identifier: NCT02680587.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hellman, S., & Weichselbaum, R. R. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.1.8 · Cited by 2,562
Stereotactic body radiation therapy: The report of AAPM Task Group 101
Benedict, S. H., Yenice, K. M., Followill, D., Galvin, J. M., Hinson, W., Kavanagh, B., Keall, P., Lovelock, M., Meeks, S., Papiez, L., et al. (2010) · Medical Physics · doi:10.1118/1.3438081 · Cited by 2,218
Self-citationPalma, D. A., Olson, R., Harrow, S., Gaede, S., Louie, A. V., Haasbeek, C., Mulroy, L., Lock, M., Rodrigues, G. B., Yaremko, B. P., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32487-5 · Cited by 1,857
The evolutionary history of lethal metastatic prostate cancer
ICGC Prostate UK Group, Gundem, G., Van Loo, P., Kremeyer, B., Alexandrov, L. B., Tubio, J. M. C., Papaemmanuil, E., Brewer, D. S., Kallio, H. M. L., Högnäs, G., et al. (2015) · Nature · doi:10.1038/nature14347 · Cited by 1,388
Genomic correlates of clinical outcome in advanced prostate cancer
Abida, W., Cyrta, J., Heller, G., Prandi, D., Armenia, J., Coleman, I., Cieslik, M., Benelli, M., Robinson, D., Van Allen, E. M., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1902651116 · Cited by 1,372
Ost, P., Reynders, D., Decaestecker, K., Fonteyne, V., Lumen, N., De Bruycker, A., Lambert, B., Delrue, L., Bultijnck, R., Claeys, T., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.4853 · Cited by 1,351
Gomez, D. R., Tang, C., Zhang, J., Blumenschein, G. R., Hernandez, M., Lee, J. J., Ye, R., Palma, D. A., Louie, A. V., Camidge, D. R., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00201 · Cited by 1,283
Parker, C. C., James, N. D., Brawley, C. D., Clarke, N. W., Hoyle, A. P., Ali, A., Ritchie, A. W. S., Attard, G., Chowdhury, S., Cross, W., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32486-3 · Cited by 1,262
Chaudhuri, A. A., Chabon, J. J., Lovejoy, A. F., Newman, A. M., Stehr, H., Azad, T. D., Khodadoust, M. S., Esfahani, M. S., Liu, C. L., Zhou, L., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0716 · Cited by 1,072
Self-citationIyengar, P., Wardak, Z., Gerber, D. E., Tumati, V., Ahn, C., Hughes, R. S., Dowell, J. E., Cheedella, N., Nedzi, L., Westover, K. D., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.3501 · Cited by 1,047
Radiotherapy induces responses of lung cancer to CTLA-4 blockade
Formenti, S. C., Rudqvist, N.-P., Golden, E., Cooper, B., Wennerberg, E., Lhuillier, C., Vanpouille-Box, C., Friedman, K., Ferrari de Andrade, L., Wucherpfennig, K. W., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0232-2 · Cited by 928 · cited 1×
“Time to first recurrence, median (range), mo 22 (9-42) 22 (9-51)”
BackgroundGolden, E. B., Chhabra, A., Chachoua, A., Adams, S., Donach, M., Fenton-Kerimian, M., Friedman, K., Ponzo, F., Babb, J. S., Goldberg, J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00054-6 · Cited by 667
Annala, M., Vandekerkhove, G., Khalaf, D., Taavitsainen, S., Beja, K., Warner, E. W., Sunderland, K., Kollmannsberger, C., Eigl, B. J., Finch, D., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0937 · Cited by 515
Nuhn, P., De Bono, J. S., Fizazi, K., Freedland, S. J., Grilli, M., Kantoff, P. W., Sonpavde, G., Sternberg, C. N., Yegnasubramanian, S., & Antonarakis, E. S. (2019) · European Urology · doi:10.1016/j.eururo.2018.03.028 · Cited by 437
Self-citationConcordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer
Wyatt, A. W., Annala, M., Aggarwal, R., Beja, K., Feng, F., Youngren, J., Foye, A., Lloyd, P., Nykter, M., Beer, T. M., et al. (2017) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djx118 · Cited by 412
Tie, J., Cohen, J. D., Wang, Y., Li, L., Christie, M., Simons, K., Elsaleh, H., Kosmider, S., Wong, R., Yip, D., et al. (2019) · Gut · doi:10.1136/gutjnl-2017-315852 · Cited by 381
Na, R., Zheng, S. L., Han, M., Yu, H., Jiang, D., Shah, S., Ewing, C. M., Zhang, L., Novakovic, K., Petkewicz, J., et al. (2017) · European Urology · doi:10.1016/j.eururo.2016.11.033 · Cited by 343
Self-citationStuder, U. E., Whelan, P., Albrecht, W., Casselman, J., de Reijke, T., Hauri, D., Loidl, W., Isorna, S., Sundaram, S. K., Debois, M., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.7423 · Cited by 327
MicroRNA Expression Characterizes Oligometastasis(es)
Lussier, Y. A., Xing, H. R., Salama, J. K., Khodarev, N. N., Huang, Y., Zhang, Q., Khan, S. A., Yang, X., Hasselle, M. D., Darga, T. E., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028650 · Cited by 281
Pitroda, S. P., Khodarev, N. N., Huang, L., Uppal, A., Wightman, S. C., Ganai, S., Joseph, N., Pitt, J., Brown, M., Forde, M., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04278-6 · Cited by 254
Moul, J. W., Wu, H., Sun, L., McLeod, D. G., Amling, C., Donahue, T., Kusuda, L., Sexton, W., O’Reilly, K., Hernandez, J., et al. (2008) · Journal of Urology · doi:10.1016/j.juro.2008.03.138 · Cited by 247
MOUL, J. W., WU, H., SUN, L., McLEOD, D. G., AMLING, C., DONAHUE, T., KUSUDA, L., SEXTON, W., O’REILLY, K., HERNANDEZ, J., et al. (2004) · Journal of Urology · doi:10.1097/01.ju.0000113794.34810.d0 · Cited by 224
Duchesne, G. M., Woo, H. H., Bassett, J. K., Bowe, S. J., D'Este, C., Frydenberg, M., King, M., Ledwich, L., Loblaw, A., Malone, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00107-8 · Cited by 219
Lussier, Y. A., Khodarev, N. N., Regan, K., Corbin, K., Li, H., Ganai, S., Khan, S. A., Gnerlich, J., Darga, T. E., Fan, H., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050141 · Cited by 201
Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer
Vandekerkhove, G., Struss, W. J., Annala, M., Kallio, H. M. L., Khalaf, D., Warner, E. W., Herberts, C., Ritch, E., Beja, K., Loktionova, Y., et al. (2019) · European Urology · doi:10.1016/j.eururo.2018.12.042 · Cited by 185
Vickers, A. J. (2006) · Journal of the Society for Integrative Oncology · doi:10.2310/7200.2006.023 · Cited by 163
Hong, J. C., Ayala-Peacock, D. N., Lee, J. T., Blackstock, A. W., Okunieff, P. G., Sung, M. W., Weichselbaum, R. R., Kao, J., Urbanic, J. J., Milano, M. T., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0195149 · Cited by 125
14q32-encoded microRNAs mediate an oligometastatic phenotype
Uppal, A., Wightman, S. C., Mallon, S., Oshima, G., Pitroda, S. P., Zhang, Q., Huang, X., Darga, T. E., Huang, L., Andrade, J., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.2920 · Cited by 110
Soldatov, A., von Klot, C. A. J., Walacides, D., Derlin, T., Bengel, F. M., Roß, T. L., Wester, H., Derlin, K., Kuczyk, M. A., Christiansen, H., et al. (2018) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2018.08.066 · Cited by 72
Damodaran, S., Lang, J. M., & Jarrard, D. F. (2019) · The Journal of Urology · doi:10.1097/ju.0000000000000117 · Cited by 61
The 46th David A. Karnofsky Memorial Award Lecture: Oligometastasis—From Conception to Treatment
Weichselbaum, R. R. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.18.00847 · Cited by 55
SABR-COMET: harbinger of a new cancer treatment paradigm
Loo, B. W., & Diehn, M. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30278-8 · Cited by 14
Self-citation
Cited by
Cornford, P., van den Bergh, R. C. N., Briers, E., Van den Broeck, T., Cumberbatch, M. G., De Santis, M., Fanti, S., Fossati, N., Gandaglia, G., Gillessen, S., et al. (2021) · European Urology · doi:10.1016/j.eururo.2020.09.046 · Cited by 1,079
The Lancet Commission on prostate cancer: planning for the surge in cases
James, N. D., Tannock, I., N'Dow, J., Feng, F., Gillessen, S., Ali, S. A., Trujillo, B., Al-Lazikani, B., Attard, G., Bray, F., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00651-2 · Cited by 738
Sandhu, S., Moore, C. M., Chiong, E., Beltran, H., Bristow, R. G., & Williams, S. G. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00950-8 · Cited by 583
Genomic and phenotypic heterogeneity in prostate cancer
Haffner, M. C., Zwart, W., Roudier, M. P., True, L. D., Nelson, W. G., Epstein, J. I., De Marzo, A. M., Nelson, P. S., & Yegnasubramanian, S. (2021) · Nature Reviews Urology · doi:10.1038/s41585-020-00400-w · Cited by 502
Contemporary radiotherapy: present and future
Chandra, R. A., Keane, F. K., Voncken, F. E. M., & Thomas, C. R. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00233-6 · Cited by 380
Metadata
- Authors
- Phillips, R., Shi, W. Y., Deek, M., Radwan, N., Lim, S. J., Antonarakis, E. S., Rowe, S. P., Ross, A. E., Gorin, M. A., Deville, C., Greco, S. C., Wang, H., Denmeade, S. R., Paller, C. J., Dipasquale, S., DeWeese, T. L., Song, D. Y., Wang, H., Carducci, M. A., Pienta, K. J., Pomper, M. G., Dicker, A. P., Eisenberger, M. A., Alizadeh, A. A., Diehn, M., & Tran, P. T.
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2020-05-01
- Volume
- 6
- Issue
- 5
- Pages
- 650
- ISSN
- 2374-2437 (ISSN-L)
- OpenAlex
- W3013251573
- Cited by
- 1,159
- References
- 32
- FWCI
- 82.75
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.